TY  - JOUR
TI  - Anti-TNF treatment in ankylosing spondylitis patients
with chronic kidney disease: Is it effective and safe?
AB  - Objective: This study aims to examine the efficacy and safety of the antitumor necrosis factor (TNF)
drugs in ankylosing spondylitis (AS) patients with chronic kidney disease.
Methods: In this study, 24 male patients with a glomerular filtration rate (GFR) of <60 mL min1 1.73
m2 were included among 863 patients who were followed-up once in 3 months regularly from 2010
to 2018 years. Twenty-four patients were chosen for the control group among 420 male patients
whose renal functions were normal using random sampling. We examined C-reactive protein, erythro-
cyte sedimentation rate, serum creatinine, and GFR values, and also the measurements of Bath Anky-
losing Spondylitis Disease Activity Index (BASDAI) were recorded at the beginning of the treatment
with anti-TNF agents and in the 3rd, 6th, 9th, 12th, and final visit months.
Results: Eleven (45.9%) of the patients included in the study were in the routine dialysis program. The
initial anti-TNF treatments were etanercept (62.5%), infliximab (16.7%), adalimumab (16.7%), and goli-
mumab (4.1%). Treatment was effective in 22 (91.7%) of the patients. When the values of the two
groups’ patients were compared at the beginning of the treatment, there was a substantial reduction
regarding BASDAI (P < .001). Pleural effusion, infective endocarditis, septic arthritis, and prosthesis
infection were major side effects (n ¼ 4). The mortality rate of the 24 patients was 29.2% (n ¼ 7).
Conclusion: This study demonstrated that anti-TNF drug treatment is effective and safe in patients
with AS who have chronic kidney disease
AU  - Yağız, Burcu
AU  - Coskun, Belkis Nihan
AU  - PEHLİVAN, Yavuz
AU  - Çorabay, Seniha
AU  - Dalkılıç, Ediz
DO  - 10.5152/eurjrheum.2022.21099
PY  - 2022
JO  - European Journal of Rheumatology
VL  - 9
IS  - 2
SN  - 2147-9720
SP  - 68
EP  - 74
DB  - TRDizin
UR  - http://search/yayin/detay/524281
ER  -